Leticia V. S.
- Country
- Spain
- Department
- Allergology
Research Overview
- Subcutaneous Dermatophagoides/Lepidoglyphus immunotherapy for moderate-to-severe allergic rhinitis/rhinoconjunctivitis with mild-to-moderate asthma: randomized placebo-controlled trial
- A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma
Data & Insights
Has run more than one trial at 2 of 37 partner sites.
Specializations
Targeted Therapy in ALK-Positive Lung Cancer
Focuses on molecular inhibition strategies for ALK-positive non‑small cell lung cancer.
- Lorlatinib versus crizotinib
- Progression‑free survival improvement
- Treatment‑naïve patient cohorts
Emphasizes precision oncology within thoracic malignancies.
HER2-Positive Early-Stage Breast Cancer
Investigates neoadjuvant and adjuvant approaches for HER2-positive early-stage breast cancer.
- Subcutaneous trastuzumab‑pertuzumab
- T‑DM1 integration
- Three‑year recurrence‑free interval
Aims to enhance cure rates while reducing chemotherapy exposure.
Allergic Rhinoconjunctivitis and Asthma
Develops allergen‑specific immunotherapy for allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae.
- SCIT extract mixtures
- Placebo‑controlled efficacy
- Global health status monitoring
Seeks durable symptom relief and improved quality of life.
Solid Tumor Therapeutics
Engages in clinical evaluation of novel agents across diverse solid tumors.
- Encorafenib/Binimetinib continuation studies
- Master protocol designs
- Safety and tolerability assessments
Supports expansion of targeted treatment options beyond organ‑specific cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.